Profile
Naamit Sher worked as the VP of Drug Development & Regulatory Affairs at Vascular Biogenics Ltd. She was also the Director of Quality Control & Quality Assurance at Interpharm Laboratories Ltd. and the Head of QC Laboratories at Teva Pharmaceutical Industries Ltd. Additionally, she held the title of Principal at Teva North America.
Dr. Sher received her undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Former positions of Naamit Sher
| Companies | Position | End |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01/01/2006 |
Teva North America | Corporate Officer/Principal | - |
Interpharm Laboratories Ltd.
Interpharm Laboratories Ltd. BiotechnologyHealth Technology Develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases | Corporate Officer/Principal | - |
| NOTABLE LABS, LTD. | General Counsel | - |
Training of Naamit Sher
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Teva North America | |
Interpharm Laboratories Ltd.
Interpharm Laboratories Ltd. BiotechnologyHealth Technology Develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases | Health Technology |
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. BiotechnologyHealth Technology Develops novel treatments for atherosclerosis and cancer | Health Technology |
- Stock Market
- Insiders
- Naamit Sher
















